Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity

Paul R. Leger; Dennis X. Hu; Bérenger Biannic; Minna Bui; Xinping Han; Emily Karbarz; Jack Maung; Akinori Okano; Maksim Osipov; Grant M. Shibuya; Kyle Young; Christopher Higgs; Betty Abraham; Delia Bradford; Cynthia Cho; Christophe Colas; Scott Jacobson; Yamini M. Ohol; Deepa Pookot; Payal Rana; Jerick Sanchez; Niket Shah; Michael Sun; Steve Wong; Dirk G. Brockstedt; Paul D. Kassner; Jacob B. Schwarz; David J. Wustrow

doi:10.1021/acs.jmedchem.0c00245

Abstract

This is the authors' abstract. We don't add key points for this paper.

demonstrated tumor growth inhibition in both p53 wildtype and p53 mutant cancer cell lines, demonstrating that USP7 inhibitors can suppress tumor growth through multiple different pathways.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Leger et al. (2020) studied this question.

synapsesocial.com/papers/6a018ba9a7a051e0e4d8aa80 https://doi.org/10.1021/acs.jmedchem.0c00245

View Full Paper

Ask AI

Bookmark

Abstract

This is the authors' abstract. We don't add key points for this paper.

demonstrated tumor growth inhibition in both p53 wildtype and p53 mutant cancer cell lines, demonstrating that USP7 inhibitors can suppress tumor growth through multiple different pathways.

Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity

Abstract

Ask about this paper

Discussion

Cite This Study

Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading